Royalty Pharma
RPRX
56.76
+0.32
+0.57%
Royalty Pharma
US · RPRX
#759 by market cap
Listed 2020
56.76
+0.32
+0.57%
Live - 5344 symbols - heartbeat 79s ago
· 2026-10-08 07:37
Pre-market
56.57
-0.33%
After-hours
56.76
0.00%
- Market cap
- 25.27B
- P/E (TTM)i
- 30.52
- P/Bi
- 3.70
- EPSi
- 1.78
- Div yieldi
- 1.60%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on RPRX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 7 analysts
Buy
Avg price target
65.71 +15.8%
Price target rangecurrent 56.76
Low62.00
Avg65.71
High70.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-23 | BofA Securities | -- | BUY | 63.00 |
| 2026-09-09 | Citi | -- | BUY | 70.00 |
| 2026-09-08 | TD Cowen | -- | BUY | 68.00 |
| 2026-09-08 | UBS | -- | BUY | 66.00 |
| 2026-08-11 | UBS | -- | BUY | 66.00 |
| 2026-08-10 | J.P. Morgan | -- | BUY | 62.00 |
| 2026-08-06 | Morgan Stanley | -- | BUY | 65.00 |
| 2026-08-06 | Citi | -- | BUY | 70.00 |
| 2026-08-06 | Goldman Sachs | -- | BUY | 66.00 |
| 2026-08-05 | Morgan Stanley | -- | BUY | 65.00 |
| 2026-07-15 | Citi | -- | BUY | 66.00 |
| 2026-07-13 | TD Cowen | -- | BUY | 65.00 |
| 2026-07-10 | BofA Securities | -- | BUY | -- |
| 2026-05-26 | Citi | -- | BUY | 66.00 |
| 2026-05-07 | BofA Securities | -- | BUY | 62.00 |
| 2026-05-07 | Morgan Stanley | -- | BUY | 64.00 |
| 2026-05-07 | Goldman Sachs | -- | BUY | 59.00 |
| 2026-05-07 | J.P. Morgan | -- | BUY | 58.00 |
| 2026-05-05 | Citi | -- | BUY | 66.00 |
| 2026-04-20 | UBS | -- | BUY | 57.00 |
| 2026-04-10 | Morgan Stanley | -- | BUY | 63.00 |
| 2026-04-08 | TD Cowen | -- | BUY | 55.00 |
| 2026-02-27 | TD Cowen | -- | BUY | 50.00 |
| 2026-02-13 | Goldman Sachs | -- | BUY | 51.00 |
| 2026-02-12 | BofA Securities | -- | BUY | 54.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
A-
Momentum strategy signal
Buy
Analyst consensus
Buy
All 3 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-05 | -- | ±5.22% | +0.47% (in line) |
| 2026/Q1 | 2026-05-06 | -- | ±5.06% | +0.56% (in line) |
| 2025/Q4 | 2026-02-11 | -- | ±8.31% | +0.09% (in line) |
| 2025/Q3 | 2025-11-05 | -- | ±6.87% | +6.82% (in line) |
| 2025/Q2 | 2025-08-06 | -- | ±5.33% | -2.08% (in line) |
| 2025/Q1 | 2025-05-08 | -- | ±9.94% | +1.07% (in line) |
| 2024/Q4 | 2025-02-11 | -- | ±5.78% | +1.67% (in line) |
| 2024/Q3 | 2024-11-06 | -- | ±6.91% | -3.27% (in line) |
| 2024/Q2 | 2024-08-08 | -- | ±9.49% | -4.04% (in line) |
| 2024/Q1 | 2024-05-09 | -- | ±7.44% | -0.07% (in line) |
| 2023/Q4 | 2024-02-15 | -- | ±8.13% | +3.23% (in line) |
| 2023/Q3 | 2023-11-08 | -- | ±6.25% | +0.25% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:37:27 · For reference only, not investment advice and not tailored to your situation.